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Background: Pertuzumab plus trastuzumab provides a more comprehensive blockade of HER2 signalling than trastuzumab alone.
Therefore, we conducted a phase IIa study of the pharmacokinetics and safety of pertuzumab plus trastuzumab and chemotherapy
in advanced gastric cancer (aGC).
Methods: Patients received pertuzumab 840mg for cycle 1 and 420mg q3w for cycles 2–6 (Arm A) or pertuzumab 840mg q3w for
six cycles (Arm B). Trastuzumab, cisplatin and capecitabine were also given for six cycles, then trastuzumab q3w until disease
progression or unmanageable toxicity. The co-primary endpoints were day 43 pertuzumab serum trough concentration (Cmin) and
safety.
Results: Thirty patients were randomised. Mean pertuzumab Cmin at day 43 was 40.0 mgml
 1 (s.d.: 17.3) in Arm A and 62.7 mgml 1
(29.1) in Arm B. Mean day 43 Cmin in Arm A wasB37% lower than that seen in metastatic breast cancer. The safety profiles were
similar between arms and treatment was well tolerated. Partial responses were achieved by 86% and 55% of patients in Arms A and
B, respectively.
Conclusions: On the basis of the pharmacokinetic and safety data, the 840mg q3w pertuzumab dose has been selected for a
phase III study of pertuzumab, trastuzumab and chemotherapy in HER2-positive aGC.
Globally, gastric cancer is the fourth most commonly occurring
cancer (Ferlay et al, 2010), with variable overall survival rates; the
5-year survival rate ranges from 10–30% in most of the world to
50–70% in Korea and Japan (Howlader et al, 2011; Matsuda and
Saika, 2013; Jung et al, 2013a; De Angelis et al, 2014). Although
surgical resection of localised gastric tumours offers a potentially
curative therapy, most patients present with inoperable, advanced
or metastatic disease requiring palliative treatment (Dicken et al,
2005), with the exception of some countries in East Asia, such as
Korea and Japan, where national screening programmes are
conducted (Dicken et al, 2005; Jung et al, 2013b). Combining
multiple chemotherapy agents has improved overall survival rates
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compared with single agents or best supportive care (Wagner et al,
2006), and the current standard chemotherapy regimen for
patients with advanced gastric cancer (aGC) contains a fluoropyr-
imidine plus a platinum compound (Jackson et al, 2009). However,
the prognosis of patients with aGC remains poor and improved
treatment options are required for this disease.
Human epidermal growth factor receptor 2 (HER2) over-
expression/amplification is an established negative prognostic
biomarker in breast cancer and occurs in B20% of cases
(Slamon et al, 1987, 1989), whereas 17–22% of gastric cancer
cases have been reported to be HER2-positive (Tanner et al, 2005;
Lordick et al, 2007; Zhang et al, 2009; Bang et al, 2010). In the
phase III ToGA trial, the addition of the HER2-targeted humanised
monoclonal antibody trastuzumab to first-line fluoropyrimidine
plus cisplatin chemotherapy significantly increased overall survival
in patients with HER2-positive advanced gastric or gastro–
oesophageal junction cancer, with further survival benefit in
patients whose tumours had high levels of HER2 expression
(immunohistochemistry (IHC) 3þ or IHC 2þ and fluorescence
in situ hybridisation-positive; Bang et al, 2010). The grade 3–4
adverse event (AE) profiles were similar between the trastuzumab
plus chemotherapy arm and the chemotherapy-only arm, with the
exception of increased rates of diarrhoea in patients receiving
trastuzumab (Bang et al, 2010). On the basis of the data from the
ToGA trial, trastuzumab was approved in combination with
capecitabine plus cisplatin or 5-fluorouracil plus cisplatin for the
first-line treatment of patients with HER2-positive metastatic
adenocarcinoma of the stomach or gastro–oesophageal junction
(Herceptin Summary of Product Characteristics, 2013). Lapatinib,
an oral tyrosine kinase inhibitor of epidermal growth factor
receptor and HER2, has also been tested in HER2-positive gastric
cancer. However, lapatinib did not improve overall survival when
combined with chemotherapy for first-line (Hecht et al, 2013) or
second-line treatment (Bang et al, 2013) of HER2-positive aGC.
Pertuzumab is a humanised monoclonal antibody that targets a
different epitope of HER2 from trastuzumab (Cho et al, 2003;
Franklin et al, 2004). Whereas trastuzumab binds to subdomain
IV of HER2 (Cho et al, 2003) to inhibit ligand-independent
signalling (Junttila et al, 2009), pertuzumab binds to subdomain II
(Franklin et al, 2004), the dimerisation domain, to inhibit HER2
heterodimerisation and, consequently, ligand-dependent signalling
(Agus et al, 2002). Pre-clinical studies have suggested that
trastuzumab and pertuzumab have complementary mechanisms
of action and that the combination of the two antibodies provides a
more efficient blockade of HER2 signalling than either antibody
alone (Nahta et al, 2004; Scheuer et al, 2009). In the CLEOPATRA
study of patients with HER2-positive metastatic breast cancer
(MBC), the combination of pertuzumab, trastuzumab and
docetaxel significantly improved progression-free (Baselga et al,
2012) and overall survival (Swain et al, 2013) compared with
placebo, trastuzumab and docetaxel. Furthermore, pre-clinical
studies of a HER2-positive human gastric cancer xenograft model
showed enhanced anti-tumour activity when pertuzumab and
trastuzumab were combined, compared with that seen with either
antibody alone (Yamashita-Kashima et al, 2011). Therefore, the
combination of pertuzumab with trastuzumab and chemotherapy
has the potential to improve survival outcomes in patients with
HER2-positive aGC compared with trastuzumab and chemother-
apy alone.
In patients with HER2-positive aGC, the observed steady-state
exposure of trastuzumab was lower than that seen with an identical
dose in MBC, and patients with trastuzumab concentrations in the
lowest quartile had a shorter median overall survival (7.7 (range,
6.3–10.6) months) than patients in the upper three quartiles (15.7
(range, 14.1–18.9) months; Yang et al, 2013). Furthermore, in a
separate analysis, patients with the lowest trastuzumab serum
trough concentrations had the highest rate of disease progression
and shortest overall survival (Cosson et al, 2014). Therefore, we
aimed to study the pharmacokinetics (PK) of pertuzumab in
combination with trastuzumab and chemotherapy to identify the
pertuzumab dose that produces a steady-state trough serum
concentration (Cmin) of X20 mgml
 1 in at least 90% of patients
with HER2-positive gastric cancer. This PK target was derived
from dose-response xenograft studies of pertuzumab administered
as a single agent showing effective tumour-growth inhibition with
serum trough concentrations of 5–25 mgml 1 (Malik et al, 2003),
and is also the PK target that was used to determine the
pertuzumab dose in breast cancer. In patients with HER2-positive
breast cancer, the PK target was achieved with a pertuzumab
loading dose of 840mg followed by 420mg q3w, a dosing regimen
that has shown promising activity in early and advanced breast
cancer treatment settings (Baselga et al, 2010; Corte´s et al, 2012;
Gianni et al, 2012; Schneeweiss et al, 2013; Swain et al, 2013).
Importantly, phase I/II trials of both weight-based and fixed
pertuzumab doses in multiple tumour types have not revealed a
maximum tolerated dose (Agus et al, 2005; Attard et al, 2007;
Albanell et al, 2008). Here we present the results of JOSHUA, a
phase IIa study of the PK and safety of two different doses of
pertuzumab in combination with trastuzumab and chemotherapy,
to identify the optimal pertuzumab dose for clinical studies in
HER2-positive gastric cancer.
MATERIALS AND METHODS
Study design and treatment. JOSHUA was a randomised,
multicentre, open-label phase IIa trial (NCT01461057) evaluating
two different doses of pertuzumab in patients with HER2-positive
advanced gastric or gastro–oesophageal junction cancer. Treatment
was given in 3-weekly cycles. Patients were randomised to receive
an initial pertuzumab dose of 840mg for cycle 1, followed by a
dose of 420mg for cycles 2–6 (Arm A) or pertuzumab 840mg for
cycles 1–6 (Arm B). Patients in both treatment arms received
cisplatin (80mgm 2) and capecitabine (1000mgm 2 BID for 14
days) for cycles 1–6; in the absence of disease progression or
unmanageable toxicity, patients could receive capecitabine for
more than six cycles, at the discretion of the investigator. All
patients received trastuzumab at 8mg kg 1 for cycle 1, followed by
6mg kg 1 for subsequent cycles, until investigator-assessed disease
progression or unmanageable toxicity. The study was approved by
the institutional review board of each participating centre or the
competent authority and ethics committee. The study was
conducted in full accordance with the International Conference
on Harmonisation Good Clinical Practice guidelines and the
Declaration of Helsinki. All patients provided written informed
consent.
The co-primary endpoints of the study were Cmin at day 43
(cycle 2 trough concentration) and safety. The aim of the PK
endpoint was to identify the pertuzumab dose that produced a
steady-state Cmin of X20 mgml
 1 in at least 90% of patients. The
aim of the safety endpoint was to assess the incidence of all AEs.
An exploratory objective of the study was to assess the anti-tumour
activity of pertuzumab in combination with trastuzumab and
chemotherapy in this disease setting.
Patient population. Patients X18 years old were eligible if they
had histologically confirmed, inoperable, locally advanced or
metastatic HER2-positive adenocarcinoma of the stomach or
gastro–oesophageal junction. HER2 positivity was defined as IHC
3þ or IHC 2þ and in situ hybridisation (ISH)-positive
(ISH positivity was defined as a HER2 :CEP17 signal ratio of
X2.0) by central testing. Eligible patients had measurable disease
or non-measurable, evaluable disease according to Response
Evaluation Criteria In Solid Tumors (RECIST) version 1.1
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(Eisenhauer et al, 2009). Patients were required to have an Eastern
Cooperative Oncology Group performance status of 0 or 1, a
baseline left ventricular ejection fraction (LVEF) of X55% and a
life expectancy ofX3 months. Patients were eligible if they had not
received prior treatment for advanced or metastatic disease; prior
(neo)adjuvant therapy was allowed if completedX6 months before
study enrolment, whereas platinum-based (neo)adjuvant therapy
was prohibited. Patients were not eligible for the study if they had a
serious cardiac illness or medical condition.
Analysis of PK. For pertuzumab PK assessment, pre-dose and
post-dose serum samples were collected at cycles 1, 2, 3, 4 and 6.
Pre-dose samples were collected up to 6 h before the administra-
tion of pertuzumab and post-dose samples were collected up to
30min after the pertuzumab infusion. The cycle 2 trough (cycle 3
pre-dose) sample had to be collected on study day 43 (21 days after
the cycle 2 dose), regardless of whether the cycle 3 dose was given,
delayed or not given. In addition, weekly serum samples were
collected in cycles 1 and 2. A validated bridging enzyme-linked
immunosorption assay was used to measure the concentration of
pertuzumab in serum samples. The assay used a monoclonal anti-
idiotype antibody to capture pertuzumab and had a minimum
quantifiable concentration in human serum of 150 ngml 1.
Assessments. For tumour response assessments, all measurable
and non-measurable, evaluable disease had to be documented at
screening and reassessed at the end of cycles 3 and 6 according to
RECIST v1.1, after which patients were followed for tumour
response according to local standards. Response was assessed by
the investigator based on physical examinations, computed
tomography scans or magnetic resonance imaging. Other methods
were allowed if they were amenable to evaluation per RECIST.
LVEF assessments by echocardiogram or multiple-gated
acquisition scan were performed at baseline and then every three
cycles until disease progression or treatment discontinuation.
LVEF assessments were performed at the treatment discontinua-
tion visit, every 6 months for the first year following treatment
discontinuation, then annually for up to 3 years following
treatment discontinuation. Patients who discontinued study
treatment permanently due to LVEF decline continued to have
LVEF assessments repeated as clinically indicated, with a
maximum interval of 3 months between assessments, until LVEF
returned to 450%, or 1 year after the treatment discontinuation
visit, whichever occurred first. Thereafter, LVEF assessments were
performed annually for up to 3 years after the treatment
discontinuation visit.
AEs were graded according to The National Cancer Institute
Common Terminology Criteria for Adverse Events (NCI-CTCAE)
version 4.0 (National Cancer Institute, Bethesda, MD, USA). Real-
time safety monitoring occurred on an ongoing basis for all
patients and expedited reporting was performed for serious AEs
and AEs of special interest. AEs and serious AEs were recorded
throughout the study and up to 6 months after the last dose of
study treatment, with the exception of cardiac AEs, which were
followed for 12 months after the last dose of study treatment, and
symptomatic LVEF, which was required to be reported up to 3
years after the last dose of study treatment. Study drug-related
serious AEs continued to be recorded regardless of the time elapsed
since the last dose of study treatment.
Statistical analysis. A sample size of 15 patients per arm was
considered sufficient to determine the dose needed to achieve the
target Cmin with an acceptable degree of precision (coefficient of
variation o15%). This was determined based on trastuzumab PK
data from the ToGA trial and the assumption that pertuzumab
behaves similarly to trastuzumab in aGC. However, due to
variability, outliers and the limited number of data points due to
patient withdrawals, it was not possible to accurately assess the
primary PK endpoint on the basis of the observed percentage of
patients who achieved the target Cmin. Therefore, a post hoc
bootstrap analysis was conducted to estimate the percentage of
patients at or above the target Cmin and the confidence interval
(CI) of this estimate (analysis performed in R Statistics Software
version 2.10.1, R Foundation for Statistical Computing, Vienna,
Austria). For each pertuzumab dose group, a sample of 15 patients
was generated on the basis of the mean and s.d. of the observed
data assuming a log-normal distribution, and the percentage of
patients with a pertuzumab Cmin of X20 mgml
 1 was computed.
The process was repeated 1000 times to generate an estimated
percentage of patients with a pertuzumab Cmin of X20 mgml
 1
and a 95% CI.
RESULTS
Patient and disease characteristics. Between December 2011 and
April 2012, 30 patients enroled into the study and 15 were
randomised into each arm. The baseline demographics and disease
characteristics of patients were generally well balanced between
arms, although there were some imbalances in terms of age and
sex, with older patients and more men in Arm A (Table 1). The
majority of patients had metastatic gastric cancer.
The data cutoff occurred on 31 December 2012, at which point
the mean follow-up time was 312 days and 260 days in Arms A
and B, respectively. Fourteen patients in Arm A and 11 patients in
Arm B had received all six cycles of pertuzumab (Table 2). Seven
patients in Arm A and three patients in Arm B were still receiving
study treatment while the remaining patients had discontinued:
eight patients in Arm A (due to disease progression) and 12
patients in Arm B (eight due to disease progression, one due to an
AE (worsening renal failure), one at the physician’s decision (due
to pneumonia), one death (fungal pneumonia) and one withdrawal
by the patient).
PK of pertuzumab. Mean pertuzumab serum concentration–time
profiles are shown in Figure 1. Pertuzumab concentrations were
similar between arms at cycle 1 (when the dose was the same for
each arm). However, from cycle 2 onwards, pertuzumab
concentrations were higher in Arm B than in Arm A, consistent
with the higher dose in Arm B. In Arm A, the mean pertuzumab
Cmin increasedB2-fold from day 22 to day 106, whereas in Arm B
the increase in mean pertuzumab Cmin over this time was slightly
higher, at B2.9-fold. Overall, pertuzumab concentrations were
dose proportional.
Fifteen patients in Arm A and 13 patients in Arm B had data
available to assess pertuzumab Cmin at day 43. One patient in Arm
B had abnormally low pertuzumab concentrations, with a day 22
Cmin below the assay’s lower limit of quantification and a day 43
Cmin of 0.610 mgml
 1. After excluding this patient from the
analysis, the day 43 mean (s.d.) pertuzumab Cmin in Arms A and B
was 40.0 mgml 1 (17.3) and 62.7 mgml 1 (29.1), respectively, and
the geometric mean Cmin in Arms A and B was 36.8 mgml
 1 and
56.4 mgml 1, respectively.
Summary box-scatter plots in Figure 2 show the day 43
pertuzumab Cmin values observed in this study and in the
pertuzumab arm of the CLEOPATRA trial, which studied HER2-
positive MBC. Mean pertuzumab Cmin with the 840/420mg dose in
HER2-positive aGC (Arm A) wasB37% lower than that observed
with the same dose in HER2-positive MBC (in CLEOPATRA).
Mean pertuzumab Cmin with the 840mg q3w dose in HER2-
positive aGC (Arm B) was similar to that observed with the
840/420mg dose in HER2-positive MBC.
As day 43 pertuzumab Cmin samples from Arm B were only
available for 12 patients, the ability to select the most appropriate
pertuzumab dose based on the observed data was limited.
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Therefore, a bootstrap analysis was conducted to estimate the
percentage of patients who achieved the target pertuzumab Cmin of
X20 mgml 1 at day 43 and the CI of this estimate. This analysis
showed that 91.6% (95% CI 78.3, 99.2) and 98.3% (95% CI 91.4,
99.97) of patients in Arms A and B, respectively, achieved the
target Cmin.
Safety. At the time of data cutoff, patients in Arm A had received
a median of six (range, 4–6) doses of pertuzumab and patients in
Arm B had received a median of six (range, 1–6) doses of
pertuzumab. Overall, the AE profiles were similar between arms.
Diarrhoea was the most common AE and was mostly grade 1–2;
onset was in cycle 1, with the frequency decreasing during
subsequent cycles. Figure 3 shows the incidence of diarrhoea at
each treatment cycle. No patient discontinued therapy due to
diarrhoea. There were 24 reports (16 in Arm A and 8 in Arm B) of
gradeX2 diarrhoea in 18 patients (11 in Arm A and 7 in Arm B).
Onset of the first incidence of gradeX2 diarrhoea in these patients
occurred on median (range) study day 12 (1–237) (study day 13
(6–237) in Arm A, study day 8 (1–16) in Arm B). There were 13
instances (8 in Arm A (in seven patients) and 5 in Arm B (in three
patients)) of capecitabine dose reduction due to an AE that
occurred either during the duration of grade X2 diarrhoea or on
day 1 of the subsequent treatment cycle, following resolution of
gradeX2 diarrhoea. For these 10 patients, initial capecitabine dose
reduction occurred on median (range) study day 35.5 (22–181)
(study day 42 (23–181) in Arm A, study day 22 (22–56) in Arm B).
The total number of gradeX3 AEs was 78 in Arm A and 60 in
Arm B and the most frequent gradeX3 AEs are shown in Table 3.
Seventy-three percent and 67% of patients in Arms A and B,
respectively, experienced at least one serious AE and the total
number of all serious AEs was 35 in Arm A and 19 in Arm B.
Serious AEs that occurred in X2 patients overall were diarrhoea,
febrile neutropenia, acute renal failure, asthenia, fatigue, gastric
obstruction, hyponatraemia, mucosal inflammation, neutropenia,
pneumonia, pulmonary embolism and vomiting. One serious
AE in Arm B (fungal pneumonia) resulted in death. This was
considered by the investigator to be related to the chemotherapy
agents. No patient experienced symptomatic heart failure. Two
patients, both in Arm A, experienced asymptomatic LVEF decline.
After delaying study treatment, their LVEF values recovered and
these patients continued receiving study treatment.
Overall response. An exploratory endpoint of the study was to
assess the anti-tumour activity of pertuzumab with trastuzumab,
cisplatin and capecitabine in patients with HER2-positive aGC
(Table 4). At the end of cycle 3, 10 (67%) and 7 (58%) patients in
Table 1. Baseline patient characteristics
Arm A:
840/420mg
pertuzumab,
n¼15
Arm B:
840mg q3w
pertuzumab,
n¼15
Age, years
Median (min–max) 67 (29–76) 59 (27–72)
o65, n (%) 6 (40.0) 10 (66.7)
Sex, n (%)
Male 14 (93.3) 10 (66.7)
Ethnicity, n (%)
Hispanic or Latino 2 (13.3) 1 (6.7)
Not Hispanic or Latino 13 (86.7) 14 (93.3)
Race, n (%)
Asian 9 (60.0) 8 (53.3)
White 6 (40.0) 7 (46.7)
Weight, kg
Median (min–max) 67.0 (47.0–83.0) 66.8 (52.0–89.0)
Extent of disease on entry, n (%)
Metastatic 13 (86.7) 12 (80.0)
Unresectable, locally advanced 2 (13.3) 3 (20.0)
Primary site, n (%)
Stomach 12 (80.0) 13 (86.7)
Gastro–oesophageal junction 3 (20.0) 2 (13.3)
Measurability, n (%)
Measurable disease 12 (80.0) 13 (86.7)
Non-measurable evaluable
disease only
3 (20.0) 2 (13.3)
Histologic subtypes, n (%)
Intestinal 6 (40.0) 5 (33.3)
Diffuse 1 (6.7) 3 (20.0)
Not known 8 (53.3) 7 (46.7)
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Figure 1. Pertuzumab concentration–time profiles. Pre-dose (trough)
and post-dose (peak) mean (±s.d.) concentrations of pertuzumab are
plotted against time for Arms A (closed circles) and B (open circles).
Table 2. Patient disposition
n (%)
Arm A:
840/420mg
pertuzumab,
n¼15
Arm B:
840mg q3w
pertuzumab,
n¼15
Completed six cycles of pertuzumab 14 (93.3) 11 (73.3)
Still on treatment 7 (46.7) 3 (20.0)
Discontinued treatment 8 (53.3) 12 (80.0)
Safety 0 (0.0) 2 (13.3)
Adverse event 0 (0.0) 1 (6.7)
Death 0 (0.0) 1 (6.7)
Non-safety 8 (53.3) 10 (66.7)
Physician decision 0 (0.0) 1 (6.7)
Progression of disease 8 (53.3) 8 (53.3)
Withdrawal by patient 0 (0.0) 1 (6.7)
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Arms A and B, respectively, had achieved a partial response,
whereas an additional 4 patients in each arm (27% and 33%,
respectively) had stable disease. One patient in each arm had
progressive disease. At the end of cycle 6, a partial response was
observed in 12 (86%) and 6 (55%) patients in Arms A and B,
respectively, whereas 2 (14%) and 3 (27%) patients, respectively,
had stable disease. Two patients in Arm B had progressive disease.
DISCUSSION
The primary objective of this study was to identify the pertuzumab
dose that produces a steady-state concentration ofX20mgml 1 in
at least 90% of patients with HER2-positive aGC. The PK data
show that, as expected, the 840mg q3w dose resulted in higher
pertuzumab concentrations overall than the 840/420mg dose. The
data demonstrate that both doses resulted in day 43 trough
concentrations above the target of 20mgml 1 in at least 90% of
patients; however, the lower bound of the 95% CI in Arm A in the
bootstrap analysis was 78.3%, suggesting a greater risk of not
achieving the PK target in at least 90% of patients with the
840/420mg pertuzumab dose and that the 840mg q3w pertuzu-
mab dose is more likely to maintain trough concentrations above
the target in at least 90% of patients. Moreover, the 840mg q3w
pertuzumab dose produced trough concentrations in patients with
HER2-positive aGC similar to those observed in HER2-positive
MBC in CLEOPATRA, whereas the 840/420mg dose produced
lower trough concentrations. Exposure-response analysis of data
from the ToGA trial in aGC showed that patients with the lowest
trastuzumab serum trough concentrations had the highest rate of
disease progression and shortest overall survival (Yang et al, 2013;
Cosson et al, 2014). Therefore, the 840mg q3w pertuzumab dose is
expected to provide greater treatment benefit than the 840/420mg
dose in patients with HER2-positive aGC.
Many population PK models have found patient demographic
factors, such as age, body weight and gender, and also receptor
number and disease-related factors, such as number of metastatic
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Figure 2. Comparison of pertuzumab trough concentrations in
JOSHUA (HER2-positive aGC) with CLEOPATRA (HER2-positive
MBC). Summary box-scatter plots of day 43 pertuzumab trough
concentrations observed in JOSHUA and CLEOPATRA (pertuzumab
arm). Black solid line¼median; box limits¼25th–75th percentiles;
whiskers¼1.5 interquartile range; circles¼ individual concentrations;
dotted line¼ 20mgml1 target.
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Figure 3. Incidence of diarrhoea (all grades) at each treatment cycle.
Table 3. Grade X3 adverse events
n (%)
Arm A:
840/420mg
pertuzumab,
n¼15
Arm B:
840mg q3w
pertuzumab,
n¼15
Total number of patients
with X1 event
14 (93.3) 12 (80.0)
Events occurring in X3 patients overall
Neutropeniaa 8 (53.3) 5 (33.3)
Anaemia 4 (26.7) 4 (26.7)
Diarrhoea 4 (26.7) 4 (26.7)
Decreased appetite 2 (13.3) 5 (33.3)
Febrile neutropenia 4 (26.7) 2 (13.3)
Fatigue 3 (20.0) 2 (13.3)
Hypokalaemia 1 (6.7) 3 (20.0)
Hyponatraemia 4 (26.7) 0 (0.0)
Nausea 3 (20.0) 1 (6.7)
Stomatitis 2 (13.3) 2 (13.3)
Hypophosphataemia 1 (6.7) 2 (13.3)
Mucosal inflammation 3 (20.0) 0 (0.0)
aCovers terms ‘neutropenia’ and ‘neutrophil count decreased’.
Table 4. Overall response rate
n (%)
Arm A:
840/420mg
pertuzumab,
n¼15
Arm B:
840mg q3w
pertuzumab,
n¼15
Total number of patients with
tumour assessment at baseline
15 (100.0) 15 (100.0)
End of Cycle 3
na 15 12
Partial response 10 (66.7) 7 (58.3)
Stable diseaseb 4 (26.7) 4 (33.3)
Progressive disease 1 (6.7) 1 (8.3)
End of Cycle 6
na 14 11
Partial response 12 (85.7) 6 (54.5)
Stable diseaseb 2 (14.3) 3 (27.3)
Progressive disease 0 (0.0) 2 (18.2)
aPercentages are based on n (number of patients with data available).
bThree patients in Arm A and two patients in Arm B had non-measurable disease.
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sites, circulating tumour receptors and tumour burden, to have a
statistically significant impact on PK (Bruno et al, 2005; Gupta
et al, 2012; Zhu et al, 2014). However, exploratory analysis did not
show any apparent correlation between PK and these covariates in
the small sample size of our study. Furthermore, no PK differences
were observed between Asian and non-Asian patients, consistent
with previous analyses (Dirks and Meibohm, 2010; Chiba et al,
2014; data not shown). As such, the reasons for the lower
pertuzumab concentrations in aGC compared with MBC are
currently unknown.
At this interim safety assessment, the combination of pertuzu-
mab, trastuzumab and chemotherapy was well tolerated. The AE
profiles were similar between arms and consistent with those
observed with trastuzumab and chemotherapy in the ToGA trial
(Bang et al, 2010) with the exception of higher rates of diarrhoea.
Events of diarrhoea in JOSHUA were mostly grade 1–2 and
occurred early during treatment, with their frequency decreasing
during subsequent cycles, particularly following cycle 6. Diarrhoea
was manageable and no patient discontinued study treatment due
to this AE. Although more patients discontinued treatment in Arm
B than Arm A (12 vs 8 patients), it is not clear whether this was due
to the higher pertuzumab dose, as AEs leading to discontinuation
were not uniform. As a pertuzumab dose of 1050mg q3w has been
shown to be safe and tolerable in phase I/II studies in a variety of
solid tumour types (Gordon et al, 2006; Attard et al, 2007; de Bono
et al, 2007; Albanell et al, 2008; Gianni et al, 2010), the similarity of
the safety profiles of the two doses in JOSHUA is not unexpected.
Preliminary data from the exploratory efficacy analysis show
that patients with HER2-positive aGC treated with the combina-
tion of pertuzumab, trastuzumab, capecitabine and cisplatin
achieved high rates of partial response (86% in Arm A and 55%
in Arm B) or stable disease (14% in Arm A and 27% in Arm B) at
the end of cycle 6. The overall response rates observed in JOSHUA
compare favourably with that seen in patients with HER2-positive
aGC treated with trastuzumab, capecitabine/fluorouracil and
cisplatin in the ToGA trial (47%; Bang et al, 2010). Due to the
small sample size and lack of a comparator arm in JOSHUA, no
firm conclusions can be drawn about the activity of the study drug
regimen or the difference between response rates in the two dose
groups. However, results from JOSHUA support further investiga-
tion of dual blockade anti-HER2 therapy with pertuzumab plus
trastuzumab in HER2-positive aGC.
In summary, a pertuzumab dose of 840mg q3w in patients with
HER2-positive aGC produces trough concentrations comparable to
those seen in HER2-positive MBC without increasing the incidence
of AEs. Therefore, the 840mg q3w pertuzumab dose has been
selected for an ongoing phase III study of first-line pertuzumab,
trastuzumab and chemotherapy in HER2-positive metastatic
gastric and gastro–oesophageal junction cancer (JACOB,
NCT01774786; Hoff et al, 2013).
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